Addendum: RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions Authors: Brandon Hogstad, Marie-Luise Berres, Rikhia Chakraborty, Jun Tang, Camille Bigenwald, Madhavika Serasinghe, Karen Phaik Har Lim, Howard Lin, Tsz-Kwong Man, Romain Remark, Samantha Baxter, Veronika Kana, Stefan Jordan, Zoi Karoulia, Wing-hong Kwan, Marylene Leboeuf, Elisa Brandt, Helene Salmon, Kenneth McClain, Poulikos Poulikakos, Jerry Chipuk, Willem J.M. Mulder, Carl E. Allen, Miriam Merad Published: 2026 Vol. 215, No. 1 | https://doi.org/10.1084/jem.20161881 | December 20, 2017 The authors wish to clarify that duplication of the “BRAFV600E + MEKi” plot in Fig. 3 B and the “MEKi” plot in Fig. 3 G was intentional. These panels represent the same experimental dataset, which was deliberately reused to facilitate comparison across different treatment conditions. Specifically, in panel B, the plot shows BRAFV600E bone marrow–derived dendritic cells treated with a MEK inhibitor. In panel G, the identical plot was intentionally included as the reference MEK inhibitor condition (right panel) to allow direct comparison with the ABT-treated condition (middle panel) using the same experimental dataset. This was indicated in the figure legend; however, the authors recognize that the wording could have been clearer. The authors apologize for any confusion and appreciate the opportunity to clarify this point. BCL-XL up-regulation via RAF/MEK/ERK signaling contributes to suppressed apoptosis in DCs. (A) Apoptosis measured in control and BRAFV600E BMDCs by Annexin V/propidium iodide (PI) staining. On D6 of culture, GM-CSF cytokine was removed from the BMDC culture, and BMDC viability was measured on D7 by flow cytometry. Dot plots show representative frequency of apoptotic Annexin+PI+ CD11c+CD11b+ BMDCs from two experiments. Bar graphs show the mean of triplicate samples representative of two experiments ± SEM (n = 3–5; control vs. BRAFV600E starved PI positivity: **, P = 0.0055; unpaired t test; baseline vs. starved control Annexin V positivity: *, P = 0.0419; unpaired t test). (B) Caspase 3/7 activation measured in control and BRAFV600E BMDCs starved of the GM-CSF growth factor overnight (***, P = 0.0008; unpaired t test), ±1 nM GSK1120212 (*, P = 0.0161; unpaired t test). Representative samples are shown in FACS plots. Bar graphs show the mean of three biological replicates representative of two experiments ± SEM. (C) BCL-XL expression was measured by western blot in BRAFV600ECD11c BMDCs starved (st) or not starved (nst) of the GM-CSF growth factor in overnight culture and harvested on D6 or D7 of culture. Representative data from two independent experiments are shown. (D and E) BCL-XL protein levels in control and BRAFV600E BMDCs as measured by flow cytometry. Representative data from at least two experiments with three biological replicates are shown. The bar graph in E represents quantification of triplicate conditions within one experiment ± SEM (**, P = 0.0089; unpaired t test). (F) Percentage of apoptotic BMDCs among control or BRAFV600E BMDCs cultured overnight with 100 nM BCL2-family inhibitor ABT-263, 1 µM ABT-263 (Annexin V: *, P = 0.0211; unpaired t test; PI: **, P = 0.0032; unpaired t test), or 1 nM GSK1120212 MEKi (Annexin V: *, P = 0.0268; unpaired t test; PI: **, P = 0.0030; unpaired t test). BMDCs were starved or nonstarved of the GM-CSF growth factor during overnight drug treatment and analyzed for apoptosis using Annexin V/PI staining by flow cytometry. Bar graphs show the mean of three biological replicates ± SEM, representative of two independent experiments. (G) Caspase 3/7 activation measuring BRAFV600E BMDCs treated with a control vehicle (***, P = 0.0004; unpaired t test) or with 1 nM GSK1120212 (*, P = 0.0118; unpaired t test), as shown in B, or in the presence of 1 µM ABT-263 (*, P = 0.0330; unpaired t test) overnight. Bar graphs show the mean results of triplicate conditions from two independent experiments ± SEM. (H) Western blot showing BCL2L1 protein levels in human LCH lesions cultured without serum overnight, then treated with BRAF or MEKi’s for 2 h. (C and H) Molecular mass is indicated in kilodaltons. (I and J) Viability of human LCH lesions cultured overnight without serum, then treated for 2 h with 1 nM GSK1120212 MEKi (I) or 1 µM ABT-263 BCL2-family inhibitor (J). Three patient samples are shown in each treatment group. Data represent means shown ± SEM. D6, day 6; D7, day 7.